Evidence map›Paper›PMID 42562214›Full record

ArticleVirologica Sinica2026

Stabilization of prefusion hMPV F improves manufacturability and protective immunity across hMPV lineages.

Changbin Qu, Jingjing Zou, Dongyu Niu, Qingxin Wu, Lijie Liu, Mengting Yu, Qiqi Zhang, Long Zhang, Shuai Wei, Wei Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Changbin QuDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China; Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China.
Jingjing ZouGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China; Institute of Pathogenic Biology, Hengyang Medical College, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China.
Dongyu NiuGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China.
Qingxin WuState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China; Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China.
Lijie LiuState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China; Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China.
Mengting YuState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China.
Qiqi ZhangState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China.
Long ZhangState Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China; State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China; Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China. Electronic address: zhang_long@gzlab.ac.cn.
Shuai WeiGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China. Electronic address: wei_shuai@gzlab.ac.cn.
Wei ZhangState Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China; State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China; Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China. Electronic address: zhang_wei2@gzlab.ac.cn.
Wei PengState Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China; Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou 510005, China; Institute of Pathogenic Biology, Hengyang Medical College, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China. Electronic address: peng_wei@gzlab.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human metapneumovirus (hMPV) is a major cause of pediatric acute lower respiratory tract infections (ALRTIs), yet vaccine development has been hindered by the intrinsic metastability of the prefusion F glycoprotein (pre-F). Here, we used a structure-based design strategy to stabilize hMPV pre-F while preserving neutralization-sensitive epitopes. By applying combined stabilizing elements, including disulfide bonds, a designed salt bridge, and a trimer-interface sequence swap, we generated VM-874, a pre-F-stabilized trimer that was expressed at high levels in 293F cells and exhibited improved thermal stability and stress-resistant antigenicity. VM-874 also retained binding to multiple conformation-sensitive monoclonal antibodies following thermal and storage stress. VM-874 elicited high serum neutralizing titers against both hMPV A2 and B1 strains and conferred protection in BALB/c mice and cotton rats, as evidenced by reduced pulmonary viral burden and attenuated lung pathology after challenge. Although VM-874 elicited antibodies that cross-bound respiratory syncytial virus (RSV) F protein, no RSV-neutralizing activity was detected, underscoring the need to distinguish cross-reactivity from heterologous protection in combined RSV/hMPV vaccine strategies.

Indexed as

MetapneumovirusParamyxoviridae InfectionsViral Fusion ProteinsViral VaccinesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCross ReactionsFemaleHumansLungMiceMice, Inbred BALB CProtein StabilitySigmodontinaeAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralViral Fusion ProteinsViral VaccinesCross-lineage immunityHuman metapneumovirusMolecular dynamicsPrefusion F (Pre-F)Structure-guided vaccine designThermal stability

Identifiers

PMID42562214
PMCPMC13556334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.